Search Results

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a change in management.

Eagle Pharmaceuticals, Inc. announced that it received a notice on May 20, 2024, from the Listing Qualifications Department of The Nasdaq Stock Market LLC advising the Company that it has initiated a process to delist the Company’s securities from Nasdaq because the Company had not filed its Form 10-Q for the quarter ended September 30, 2023 and its Form 10-K for the year ended December 31, 2023 by May 13, 2024.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,793,813 (“the ‘813 patent”) entitled “Pemetrexed Formulations.” Eagle has submitted the patent for listing in the U.S. Food and Drug Administration’s Orange Book.

Eagle Pharmaceuticals, Inc. today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulpride as a prevention of postoperative nausea and vomiting (PONV) in pediatric patients from birth (full-term) until 17 years of age at the upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting, which is being held May 2-4, 2024.

Dovetail Genomics, a pioneering leader in the development of genomic solutions, announced a new strategic partnership with Australian Genome Research Facility.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023.

[BELKIN Vision], an innovator in ophthalmic medical solutions, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its glaucoma laser, the Eagle device. A Q-switched, 532 nm-wavelength, frequency-doubled Nd:YAG laser, the Eagle is intended for use in performing selective laser trabeculoplasty (SLT).

Reveal Genomics ® HER2DX ® Genomic Test Demonstrates Significant Potential in HER2-Positive Advanced Gastric Cancer.